Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer.
about
Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: patient selection and special considerations.Current treatment strategies for advanced prostate cancer.PARP inhibitors for homologous recombination-deficient prostate cancer.Prognostic and predictive clinical factors in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel.
P2860
Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Randomized, Noncomparative, Ph ...... ion-Resistant Prostate Cancer.
@ast
Randomized, Noncomparative, Ph ...... ion-Resistant Prostate Cancer.
@en
type
label
Randomized, Noncomparative, Ph ...... ion-Resistant Prostate Cancer.
@ast
Randomized, Noncomparative, Ph ...... ion-Resistant Prostate Cancer.
@en
prefLabel
Randomized, Noncomparative, Ph ...... ion-Resistant Prostate Cancer.
@ast
Randomized, Noncomparative, Ph ...... ion-Resistant Prostate Cancer.
@en
P2093
P2860
P50
P356
P1476
Randomized, Noncomparative, Ph ...... ion-Resistant Prostate Cancer.
@en
P2093
Ada Gjyrezi
Atef Zaher
Che-Kai Tsao
Conor N Gruber
Costantine Albany
David M Nanus
Emmanuel S Antonarakis
Giuseppe Galletti
Guru Sonpavde
P2860
P304
P356
10.1200/JCO.2017.72.4138
P407
P577
2017-06-20T00:00:00Z